Clinical trials: Nervousness
Growth Hormone Deficiency Without Epiphyseal Closure
Ngenla Subcutaneous Injection Special Investigation
The purpose of this study is to learn about the long-term safety and effects of Ngenla. Ngenla is approved for treatment of GHD (Growth hormone deficiency) without epiphyseal closure under daily medical practice.
- Trial name
- NCT05602766
- Testing
- NGENLA (Somatrogon)
- Where
- Japan
- Volunteers
- 1 people
- Sponsor
- Pfizer
Leber's Hereditary Optic Neuropathy (LHON)
Post Authorisation Safety Study With Raxone in LHON Patients
This study is a multicentre, prospective, non-interventional post-authorisation safety study (PASS) of the clinical outcomes for patients with LHON treated with Raxone®. No medication will be provided as part of this study.
- Trial name
- PAROS (NCT02771379)
- Testing
- Idebenone
- Where
- 26 sites in Austria, France and 4 more
- Volunteers
- 229 people
- Sponsor
- Santhera Pharmaceuticals
Migraine
Single-Ascending Dose Study of AMG 333 in Healthy Subjects and Subjects With Migraines
The primary purpose of this study is to determine whether AMG 333 is safe and well tolerated in healthy subjects and subjects with migraines.
- Trial name
- NCT01953341
- Testing
- AMG 333
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Amgen
Epilepsy, Focal-Onset Seizure
Cenobamate in Adults With Focal-Onset Seizures
The BLESS Study contributes to filling this information gap by collecting data from the Italian clinical practice and the Compassionate Use Program, to better characterize the clinical profile of cenobamate describing its…
- Conditions
- Epilepsy, Focal-Onset Seizure, Neurological Disorder
- Trial name
- BLESS (NCT05859854)
- Where
- 10 sites in Italy
- Volunteers
- 936 people
- Sponsor
- Aziende Chimiche Riunite Angelini Francesco S.p.A
Wilson Disease
Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease
The study will evaluate the efficacy and safety of ALXN1840 (formerly called WTX101) administered for 48 weeks compared to standard of care (SoC) in Wilson Disease (WD) participants aged 12 and older in the Primary Evaluation…
- Trial name
- NCT03403205
- Testing
- ALXN1840, SoC Therapy
- Where
- 56 sites in United States, Australia and 20 more
- Volunteers
- 214 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Cerebral Palsy
Study in Children Who Have Switched to Isosource Junior Mix Formula
A Retrospective study In Children who have switched to Isosource Junior Mix formula (RICIMIX study) will review paediatric children > 12 months of age who require Isosource Junior Mix as an enteral tube feeding formula and have…
- Trial name
- NCT05020756
- Testing
- Isosource Junior Mix
- Where
- United Kingdom
- Volunteers
- 43 people
- Sponsor
- Société des Produits Nestlé (SPN)
Restless Legs Syndrome
Long-term Efficacy and Safety of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients
The objective of this study is to evaluate the efficacy and safety of ASP8825 (gabapentin enacarbil) for long-term treatment of restless legs syndrome patients.
- Trial name
- NCT02658188
- Testing
- ASP8825
- Where
- 10 sites in Japan
- Volunteers
- 182 people
- Sponsor
- Astellas Pharma Inc
Parkinson's Disease
An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advance-Stage Parkinson's Disease
The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of the Rotigotine patch in subjects with advanced-stage idiopathic Parkinson's Disease.
- Trial name
- SP715 (NCT00594386)
- Testing
- Rotigotine
- Where
- 41 sites in United States, Canada
- Volunteers
- 258 people
- Sponsor
- UCB Pharma
Bipolar Disorder
Open Label Extension Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder
This extension study is designed to assess the long-tem tolerability and safety of licarbazepine in patients who completed the 6-week double-blind study CLIC477D2303.
- Trial name
- NCT00139594
- Testing
- licarbazepine
- Where
- 44 sites in United States, Austria and 11 more
- Volunteers
- 181 people
- Sponsor
- Novartis
Microcephaly, Congenital Infection
Surveillance of Zika-related Microcephaly in Sub-Saharan Africa and Asia
This study will explore whether ZIKV is currently responsible for neurological complications, and particularly microcephaly, in Aedes-infested regions of Sub-Saharan Africa (SSA) and Asia.
- Trial name
- NCT03922594
- Testing
- Differential diagnosis for infectious causes of microcephaly
- Where
- 8 sites in Cameroon, China and 3 more
- Volunteers
- 150 people
- Sponsor
- Institut Pasteur
Stroke
The Evaluation of Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of JPI-289 in Healthy Male Volunteers
Double blind, randomized, placebo control, multiple dose, dose escalation study
- Trial name
- NCT02396069
- Testing
- JPI-289
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Migraine
A Study to Compare the Blood Levels of Two Dosage Formulations of the Study Medicine in Healthy Adults
The purpose of this study is to assess the bioequivalence of an alternative ODT formulation (ODT2) versus the approved ODT formulation of a CGRP receptor antagonist in healthy adult participants under fasting conditions.
- Trial name
- NCT07594769
- Testing
- ODT2 Test formulation, ODT Reference formulation
- Where
- Belgium
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Pfizer
Progressive Supranuclear Palsy, Corticobasal Degeneration
Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers
This study will evaluate flortaucipir for brain imaging of tau in subjects with progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and healthy volunteers.
- Trial name
- NCT02167594
- Testing
- Flortaucipir F18, Brain PET scan
- Where
- 5 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Parkinson Disease
Pharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa/Carbidopa
To investigate the pharmacokinetics of levodopa when administered concomitantly with BIA 9-1067 or 1 hour after.
- Trial name
- NCT01533077
- Testing
- BIA 9-1067, Sinemet® 100/25 mg
- Where
- Canada
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Alzheimer's Disease
Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease
This study aims to compare the effects of RO7568282 versus a placebo in people in the early stages of Alzheimer's disease (AD).
- Trial name
- TARBELA-AD (NCT07781657)
- Testing
- RO7568282
- Where
- United States
- Volunteers
- 450 people
- Sponsor
- Hoffmann-La Roche
Hearing Loss, Ear Diseases
Clinical Evaluation of a Cochlear Implant Sound Processor
This is a prospective within-subjects repeated-measures study that will enroll 24 adult users implanted with a HiResolution Bionic Ear System (HiRes 90K or newer).
- Conditions
- Hearing Loss, Ear Diseases, Hearing Disorders, Otorhinolaryngologic Diseases
- Trial name
- NCT04237207
- Testing
- Naída Cochlear Implant Q90 sound processor (Naida CI Q90) & software, 301-M062 sound processor & software
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- Advanced Bionics
Carcinoma, Non-Small-Cell Lung
Dose Escalating Study of the Safety and Efficacy of Patupilone, q3w, in Patients With Non-small Cell Lung Cancer
The study objective is to evaluate the maximum tolerated dose, safety and efficacy of patupilone in patients with NSCLC who have progressed after prior chemotherapy.
- Trial name
- NCT00171834
- Testing
- Patupilone
- Where
- 4 sites in United States
- Volunteers
- 89 people
- Sponsor
- Novartis Pharmaceuticals
Epilepsy
Study to Evaluate the Long-term Safety and Tolerability of USL261 in Patients With Seizure Clusters
The purpose of this study is to examine the long-term safety and tolerability of USL261 in the treatment of seizure clusters.
- Trial name
- NCT01529034
- Testing
- USL261
- Where
- 58 sites in United States, Australia and 8 more
- Volunteers
- 175 people
- Sponsor
- UCB Biopharma S.P.R.L.
Insomnia
A Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicenter Outpatient Trial Of PD 0200390 In Adults With Primary Insomnia
To demonstrate efficacy and characterize the dose response relationship of PD 0200390 on subjective wake after sleep onset in subjects with primary insomnia.
- Trial name
- NCT00569972
- Testing
- PD 0200390
- Where
- 84 sites in United States, Canada
- Volunteers
- 682 people, healthy volunteers welcome
- Sponsor
- Pfizer
Parkinson's Disease
Single Ascending Dose Study of PRX002 in Healthy Subjects
This single ascending dose study is to determine safety, tolerability, pharmacokinetics and immunogenicity of PRX002 in approximately 40 healthy subjects.
- Trial name
- NCT02095171
- Testing
- PRX002
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Prothena Biosciences Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.